Disposition of [14C]ruboxistaurin in humans

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1909-1917

  Burkey, Jennifer L ^a   Campanale, Kristina M ^b   Barbuch, Robert ^b   O'Bannon, Douglas ^b   Rash, James ^b   Benson, Charles ^b   Small, David ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; LY 338522; PROTEIN KINASE C; RUBOXISTAURIN; UNCLASSIFIED DRUG; CARBON; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C BETA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RADIOCHROMATOGRAPHY; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; FECES; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; URINE;

ADMINISTRATION, ORAL; ADULT; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; FECES; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; MOLECULAR STRUCTURE; PROTEIN KINASE C; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 33751089351     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009894     Document Type: Article

References (23)

1. Aiello LP, Vignoti L, Sheets MJ, Zhi E, Grach A, Dans MD, Milton RC, and the PKC-DRS2 Study Group (2005) The effect of the PKC-inhibitor ruboxistaurin on moderate visual loss: the PKC-DRS2 trial baseline characteristics and preliminary results. Presented at the American Academy of Ophthalmology Annual Meeting, Chicago, IL, October 14, 2005.
2. β-selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes 48 (Suppl 1):A19.
3. Ayo SH, Radnik R, Garoni JA, Troyer DA, and Kreisberg JI (1991) High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 261:F571-F577.
4. 14C] ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by LC/MS and NMR spectroscopy. Drug Metab Dispos 34:213-224.
5. Beckman JA, Goldfine AB, Gorden MB, Garrett LA, and Creager MA (2002) Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107-111.
6. Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, and Farid NA (2002) Disposition of LY333531, a selective protein kinase Cβ inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 32:1045-1052.
7. Craven PA, Davidson CM, and DeRubertis FR (1990) Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 39:667-674.
8. Craven PA and DeRubertis FR (1989) Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Investig 83:1667-1675.
9. Danis RP, Bingaman DP, Jirousek MR, and Yang Y (1998) Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC β inhibition with LY333531. Investig Ophthalmol Vis Sci 39:171-179.
10. Demolle D, De Suray JM, and Onkelinx C (1999) Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC beta inhibitor, in healthy subjects [abstract], in American Society for Clinical Pharmacology and Therapeutics 100th Annual Meting; 1999 March 18-20; San Antonio, TX. Clin Pharmacol Ther 65:189, Abstract PIII-50.
11. Demolle D, de Suray JM, Vandenhende F, and Onkelinx C (1998) LY333531 single escalating oral dose study in healthy volunteers. Diabetologia 41 (Suppl 1):A1-A354.
12. DeRubertis FR and Craven PA (1994) Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43:1-8.
13. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, and King GL (1992) Preferential elevation of protein kinase C isoform β2 and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89:11059-11063.
14. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, et al. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science (Wash DC) 272:728-731.
15. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH III, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, et al. (1996) (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-H][1,4,13]-oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem 39:2664-2671.
16. Kikkawa R, Haneda M, Uzu T, Koya D, Sugimoto T, and Shigeta Y (1994) Translocation of protein kinase C α and ζ in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 37:838-841.
17. Kowluru R, Jirousek M, Stramm L, Engerman R, and Kern T (1996) Diabetes-induced disorders of retinal protein kinase C and Na,K-ATPase are inhibited by LY333531. Diabetes 45 (S2):16A.
18. Kowluru RA, Jirousek MR, Stramm LE, Farid NA, Engerman RL, and Kern TS (1998) Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C ATPases. Diabetes 47:464-469.
19. [PKC-DRS] The PKC-DRS Study Group (2005) The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188-2197.
20. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, and King GL (1993) Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265:E783-E793.
21. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, and Anderson PW (2005) The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690.
22. Williams B and Schrier RW (1992) Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes 41:1464-1472.
23. Williams B and Schrier RW (1993) Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Investig 92:2889-2896.